The Catholic University of Korea Incheon St. Mary’s Hospital (President Seung-mo Hong, Monsignol) announced on the 26th that it had recently introduced tDCS (transcranial Direct Current Stimulation) and Deep TMS (Transcranial Magnetic Stimulation) equipment, respectively.
The transcranial direct current stimulation treatment equipment treats the disease by transmitting a minute current (1.5mA~2.0mA) to the frontal lobe to the brain cortex of the lowered frontal lobe while the patient wears a headband-shaped headband. When the medical staff enters prescription information such as the strength of current, stimulation time and frequency like a conventional drug prescription in the hospital station, the patient uses a portable module that stores the prescription history, a headband that delivers the prescribed electrical stimulation, and a sponge. can be used for treatment. In particular, it has the advantage of enabling effective treatment and management by monitoring patient compliance through the system.
Professor Song In-wook of the Department of Neurology at the Catholic University of Korea Incheon St. Mary’s Hospital said, “Transcranial DC stimulation therapy is considered safe, easy and convenient to use without concern regarding systemic side effects, so we are considering home treatment in the future.” “Recently, as a new treatment for depression, As it has been recognized, it has opened a new chapter in the treatment of neurodegenerative diseases such as cognitive decline and Parkinson’s syndrome, including dementia, which often accompanies depressive symptoms.”
In addition, Incheon St. Mary’s Hospital Brain Hospital introduced transcranial magnetic stimulation therapy equipment for the first time in the domestic general hospital level. Transcranial magnetic stimulation therapy stimulates nerve cells in the brain with magnetic fields to increase the secretion of dopamine and serotonin.
The deep transcranial magnetic stimulation (Deep TMS) equipment stimulates the brain parenchyma more deeply than the existing general TMS equipment with patented technology that has been approved by the U.S. Food and Drug Administration (FDA) and certified by the European Union (CE). If the patient wears a helmet, the treatment is performed for a short time of regarding 20 minutes, so even if the head is moved, it can stimulate the target area more stably than with existing equipment. Clinical results show that it has the strongest therapeutic effect among the existing TMS treatments, and it is confirmed that the treatment effect is 6 times higher than that of drug treatment.
Professor Song In-wook said, “Recently, with the rapid entry into an aging society, treatment and management of neurodegenerative diseases such as dementia and Parkinson’s syndrome are emerging as important social issues, but there are still few treatments that show satisfactory therapeutic effects for these diseases.” Transcranial DC electrical stimulation therapy, which has recently been recognized as a new medical treatment, is a non-invasive non-drug treatment that has conducted many studies centered on Incheon St. Mary’s Hospital for the treatment of neurodegenerative diseases such as cognitive decline and Parkinson’s syndrome. It will help a lot with management.”
Professor Song also said, “Transcranial magnetic stimulation therapy is a treatment with many research results for the treatment of intractable pain such as headache, dizziness, dementia, depression, Parkinson’s syndrome, neuropathic pain or myofascial pain syndrome worldwide.” “In particular, the transcranial magnetic stimulation device introduced this time not only stimulates the brain more deeply than the existing machine, but has also been recognized for its safety and effectiveness in the United States and Europe for better therapeutic effects. The expectations are high,” he said.